Food supplements
Healthy cooking
Breakfast
Keto products
Healthy snacks
Accessories & equipment
Today's deals
Ozempic, Wegovy, Mounjaro, orforglipron and retatrutide: an update on 2026
Medicines based on GLP-1e have revolutionised the treatment of obesity. They have also led to confusion regarding trade names, active ingredients, indications and trial results. Here is an update on the 14 August 2026, with one key rule: a medicine authorised in the United States or Europe is not automatically available or authorised in Morocco.
One molecule, several brands and uses
- Semaglutide: Ozempic is a brand intended for type 2; Wegovy is the brand designed for chronic weight management. Using ‘Ozempic’ as a universal synonym for weight-loss treatment therefore creates confusion regarding its intended use.
- Tirzepatide: Mounjaro is indicated for type 2; Zepbound is indicated for chronic weight management in countries where this indication is authorised. The active ingredient is the same, but the labelling and regulatory status differ.
- Orforglipron: This oral non-peptide GLP-1, marketed in the United States under the name Foundayo, received FDA approval on 1April 2026 for the chronic management of weight in certain adults. This US approval does not prejudge its status in Morocco.
- Retatrutide: Triple GIP/GLP-1/glucagon agonist, still at the experimental stage. Lilly announced in 2026 very significant phase 3 results, but expects to submit a regulatory application in 2027. As of August 2026, it is therefore not an approved medicine.
How do they work?
GLP-1e increases feelings of fullness, slows gastric emptying and helps regulate blood sugar levels. Tirzepatide also acts on the GIP receptor. Retatrutide additionally targets the glucagon receptor. This multi-targeted approach may enhance weight loss, but it is not possible to draw conclusions regarding long-term safety until the data have been fully reviewed by the authorities.
The figures are not directly comparable
The percentages from two different trials do not constitute a direct comparison: the study populations, duration, monitoring and analytical methods differ. In the Phase 2 trial published at 2023, the highest dose of retatrutide resulted in an average weight loss of 24,2 % to 48 weeks. In 2026, Lilly announced 28,3 % to 80 weeks in TRIUMPH-1, but these were Phase 3 results reported by the sponsor. The full regulatory assessment is still pending.
Adverse effects and high-risk situations
The most common side effects are digestive: nausea, vomiting, diarrhoea, constipation, acid reflux and a marked loss of appetite. A gradual medical titration can sometimes minimise these problems. Dehydration, persistent abdominal pain, repeated vomiting or signs of hypoglycaemia require prompt medical attention. Pregnancy, medical history, other treatments and planned surgery must be discussed with the prescribing doctor.
The treatment does not undo the foundations
The WHO considers obesity to be a chronic condition and recommends incorporating these medicines into a comprehensive management plan: a healthy diet, physical activity, behavioural support and long-term monitoring. The right treatment is not ‘the drug that causes the greatest weight loss’ but the one whose indication, benefits, risks, cost and long-term suitability are tailored to the patient.
